{"id":3854,"date":"2017-05-04T12:00:11","date_gmt":"2017-05-04T10:00:11","guid":{"rendered":"https:\/\/ibtherapeutics.com\/sv\/mfn_news\/infant-bacterial-therapeutics-ab-publ-ibt-delarsrapport-1-januari-31-mars-2017\/"},"modified":"2023-10-02T13:51:47","modified_gmt":"2023-10-02T11:51:47","slug":"infant-bacterial-therapeutics-ab-publ-ibt-delarsrapport-1-januari-31-mars-2017","status":"publish","type":"mfn_news","link":"https:\/\/ibtherapeutics.com\/sv\/pressmeddelanden\/infant-bacterial-therapeutics-ab-publ-ibt-delarsrapport-1-januari-31-mars-2017\/","title":{"rendered":"Infant Bacterial Therapeutics AB (publ), (IBT) Del\u00e5rsrapport 1 januari – 31 mars 2017"},"content":{"rendered":"
<\/div>\n

VD kommenterar<\/strong><\/p>\n

"IBTs verksamhet kommer under innevarande \u00e5r att vara fokuserat p\u00e5 slutf\u00f6randet av fas ll-studien och planering inf\u00f6r en efterf\u00f6ljande klinisk fas lll-studie. Som tidigare meddelats kommer en fas lll-studie att kr\u00e4va kapital. IBT jobbar aktivt med flera potentiella finansieringsm\u00f6jligheter och s\u00f6ker efter partners som kan bidraga med resurser till det fortsatta utvecklingsprogrammet. Vi f\u00f6rv\u00e4ntar oss att f\u00e5 b\u00e4ttre f\u00f6rst\u00e5else f\u00f6r hur myndigheter och experter ser p\u00e5 v\u00e5rt nya projekt IBP-1016, vidare f\u00f6rv\u00e4ntar vi oss att ha fas II (NCT02472769) resultat, samt planera ans\u00f6ka till Nasdaq Stockholms huvudmarknad."<\/p>\n

Staffan Str\u00f6mberg
VD<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Utvalda finansiella data i sammandrag<\/strong><\/td>\n<\/td>\n<\/tr>\n
<\/strong><\/td>\n <\/strong><\/td>\n 2017
jan-mar<\/strong><\/td>\n		 2016
jan-mar<\/strong><\/td>\n		 2016
jan-dec<\/strong><\/td>\n<\/tr>\n
<\/strong><\/td>\n <\/strong><\/td>\n <\/strong><\/td>\n <\/strong><\/td>\n <\/strong><\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Nettooms\u00e4ttning, tkr<\/td>\n<\/td>\n 117<\/td>\n –<\/td>\n 162<\/td>\n<\/tr>\n
R\u00f6relseresultat, tkr<\/td>\n<\/td>\n -8\u00a0563<\/td>\n -5\u00a0103<\/td>\n -38\u00a0090<\/td>\n<\/tr>\n
Resultat efter skatt, tkr<\/td>\n<\/td>\n -8\u00a0563<\/td>\n -5\u00a0165<\/td>\n -38\u00a0106<\/td>\n<\/tr>\n
Balansomslutning, tkr<\/td>\n<\/td>\n 100\u00a0925<\/td>\n 55\u00a0593<\/td>\n 110\u00a0109<\/td>\n<\/tr>\n
Periodens kassafl\u00f6de, tkr<\/td>\n<\/td>\n -9\u00a0113<\/td>\n -6\u00a0782<\/td>\n 49\u00a0375<\/td>\n<\/tr>\n
Likvida medel, tkr<\/td>\n<\/td>\n 84\u00a0673<\/td>\n 37\u00a0629<\/td>\n 93\u00a0786<\/td>\n<\/tr>\n
Resultat per aktie f\u00f6re och efter utsp\u00e4dning (SEK)<\/td>\n -1,56<\/td>\n -2,82<\/td>\n -8,42<\/td>\n<\/tr>\n
Eget kapital per aktie (SEK)<\/td>\n<\/td>\n 17,56<\/td>\n 26,73<\/td>\n 19,12<\/td>\n<\/tr>\n
Soliditet, %<\/td>\n<\/td>\n 96%<\/td>\n 91%<\/td>\n 96%<\/td>\n<\/tr>\n
<\/td>\n<\/tr>\n<\/table>\n

V\u00e4sentliga h\u00e4ndelser under f\u00f6rsta kvartalet 2017<\/strong><\/p>\n